Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

708.67 +15.17 (+2.19%)
Streaming Delayed Price Updated: 1:48 PM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
57 58 Next >
News headline image
Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study ↗
Regeneron's EYLEA HD met key goals in the Phase 3 QUASAR trial for macular edema after retinal vein occlusion, with FDA submission expected in Q1 2025. 
Via Benzinga
News headline image
Stocks Slip As Strong November Retail Sales Raise Concerns Over 2025 Fed Rate Cuts ↗
Wall Street began Tuesday’s session on a weaker note, with major indices slipping after November's robust retail sales report reignited investor concerns that the Federal Reserve might hold back... 
Via Benzinga
Topics Economy
News headline image
What 25 Analyst Ratings Have To Say About Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Pharmaceuticals Unusual Options Activity ↗
 
Via Benzinga
News headline image
Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking ↗
 
Via Benzinga
News headline image
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf? ↗
The weight-loss drugs space continues to heat up. Here's the latest news from the segment. 
Via Investor's Business Daily
News headline image
Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Peering Into Regeneron Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
Check Out What Whales Are Doing With REGN ↗
 
Via Benzinga
News headline image
Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money' ↗
Navitas Semiconductor is losing money according to Jim Cramer. LandBridge Company is a winner, while Regeneron is facing sales challenges. 
Via Benzinga
News headline image
It’s Been A Tough Month For Healthcare Stocks ↗
It’s been a very difficult month for the healthcare sector not only because of disappointing company news but also disruption caused by the election and future policy issues. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
28 Analysts Have This To Say About Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
Assessing Regeneron Pharmaceuticals's Performance Against Competitors In Biotechnology Industry ↗
 
Via Benzinga
News headline image
Not-So-Big Pharma ↗
Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration. 
Via Talk Markets
News headline image
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease ↗
Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a decision expected by April 2025. 
Via Benzinga
News headline image
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Top Growth Stocks to Buy on the Dip ↗
Their recent issues are nothing to fret over for investors focused on the long game. 
Via The Motley Fool
News headline image
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease ↗
After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options. 
Via Benzinga
News headline image
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 Recession-Resistant Stocks: Low Beta, High Margins, Low Debt
Check out these three stocks with financial metrics showing recession resistance and underlying business dynamics to back them up. 
Via MarketBeat
Topics Bankruptcy Bonds Economy
News headline image
Is It Time to Buy October's Worst-Performing Nasdaq Stocks? ↗
Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today. 
Via The Motley Fool
News headline image
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say ↗
Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics market. 
Via Benzinga
News headline image
Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required ↗
A bit of earnings and election jitters roiled the market last week reordering the leaderboard in biopharma stocks. 
Via Talk Markets
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.